Nicola Klein to Respiratory Syncytial Virus, Human
This is a "connection" page, showing publications Nicola Klein has written about Respiratory Syncytial Virus, Human.
Connection Strength
0.545
-
Maternal Vaccination vs Nirsevimab Use and Respiratory Syncytial Virus Infection Among Full-Term Infants. JAMA Netw Open. 2026 Oct 01; 9(10):e2636760.
Score: 0.243
-
Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children. J Pediatric Infect Dis Soc. 2023 May 31; 12(5):273-281.
Score: 0.193
-
Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalink. Vaccine. 2025 Nov 20; 67:127873.
Score: 0.057
-
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19; 404(10462):1547-1559.
Score: 0.053